In its inaugural edition, Servier digital magazine, Insights, features Aitia’s Gemini Digital Twins in its “Science Calling” section. The conversion of causal AI and Gemini Digital Twins with industrial expertise holds the potential to significantly expedite R&D phases and streamline the identification of new targets. In May 2023, Aitia and Servier inked a multi-year agreement with the objective of uncovering, validating, and advancing novel drug targets and candidates for pancreatic cancer, ranked as the world’s 7th deadliest cancer form.
Full article on Servier digital magazine Insights, here.